Fluidigm Co. (FLDM) Shares Bought by Bank of New York Mellon Corp

Share on StockTwits

Bank of New York Mellon Corp raised its stake in Fluidigm Co. (NASDAQ:FLDM) by 6.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 458,681 shares of the medical research company’s stock after acquiring an additional 29,310 shares during the quarter. Bank of New York Mellon Corp owned approximately 1.17% of Fluidigm worth $3,953,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in FLDM. BlackRock Inc. boosted its stake in Fluidigm by 9.1% in the fourth quarter. BlackRock Inc. now owns 2,139,878 shares of the medical research company’s stock valued at $18,445,000 after acquiring an additional 178,429 shares during the last quarter. Vanguard Group Inc lifted its stake in shares of Fluidigm by 9.5% during the 3rd quarter. Vanguard Group Inc now owns 1,410,526 shares of the medical research company’s stock valued at $10,565,000 after buying an additional 121,815 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Fluidigm by 9.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,410,526 shares of the medical research company’s stock valued at $10,565,000 after buying an additional 121,815 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Fluidigm by 7.7% during the 3rd quarter. Renaissance Technologies LLC now owns 1,152,800 shares of the medical research company’s stock valued at $8,634,000 after buying an additional 82,300 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Fluidigm by 739.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 72,339 shares of the medical research company’s stock valued at $542,000 after buying an additional 63,721 shares in the last quarter. Hedge funds and other institutional investors own 71.65% of the company’s stock.

FLDM has been the topic of a number of recent research reports. Zacks Investment Research cut shares of Fluidigm from a “hold” rating to a “sell” rating in a research note on Wednesday, January 16th. ValuEngine upgraded shares of Fluidigm from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. BidaskClub upgraded shares of Fluidigm from a “hold” rating to a “buy” rating in a research note on Thursday, December 27th. UBS Group initiated coverage on shares of Fluidigm in a research note on Friday, March 15th. They set a “neutral” rating and a $14.00 price target on the stock. Finally, Piper Jaffray Companies upped their price target on shares of Fluidigm from $10.00 to $14.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $14.00.

Shares of FLDM stock opened at $13.23 on Wednesday. The company has a market cap of $936.88 million, a P/E ratio of -16.54 and a beta of 2.42. The company has a debt-to-equity ratio of 2.39, a quick ratio of 3.04 and a current ratio of 3.38. Fluidigm Co. has a 12 month low of $4.65 and a 12 month high of $14.90.

Fluidigm (NASDAQ:FLDM) last announced its quarterly earnings results on Thursday, February 7th. The medical research company reported ($0.18) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.07. The company had revenue of $32.33 million for the quarter, compared to analysts’ expectations of $30.55 million. Fluidigm had a negative net margin of 52.24% and a negative return on equity of 71.42%. As a group, research analysts forecast that Fluidigm Co. will post -0.58 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Macon Daily and is the sole property of of Macon Daily. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://macondaily.com/2019/04/17/fluidigm-co-fldm-shares-bought-by-bank-of-new-york-mellon-corp.html.

About Fluidigm

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.

Recommended Story: Why are gap-down stocks important?

Institutional Ownership by Quarter for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.